- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06177977
SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs) (SS-HH-OCT)
Ultracompact Hand-Held Swept-Source Optical Coherence Tomography (SS-HH-OCT) as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)
Study Overview
Detailed Description
What photoreceptor degenerative changes take place in children with early-onset inherited retinal dystrophies, and how is photoreceptor development in this patient population affected by genetic defects?
Our novel investigational SS-HH-OCT system features high scanning speed, long laser wavelength, and an ergonomic light-weight handheld design. The investigators hypothesize that imaging with this system will enable us to characterize early-onset retinal dystrophies (EORD)-associated PDCs in young children. To this end, the investigators propose the following specific aims:
Specific Aim 1: Optimize and demonstrate reproducibility of SS-HH-OCT imaging protocols to visualize photoreceptor development and degeneration in children with and without EORDs.
Specific Aim 2: Use SS-HH-OCT parameters to characterize biomarkers of foveal photoreceptor development and degeneration in children with EORDs versus healthy controls.
A total of 80 participants will be enrolled in this study. Participants' age between 0 through 8 years (<9 years).
For children with EORD, successful completion of this study will result in 1) a framework for reproducible OCT imaging; 2) characterization of biomarkers of retinal degeneration; 3) establishment of reference data by genetic variants 4) insights into foveal development. Additionally, this study will set pilot data of structure-function data and timeline of photoreceptor degeneration for future NIH funded studies.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michelle N McCall, MCAPM, BA
- Phone Number: (919) 684-0544
- Email: michelle.mccall@duke.edu
Study Contact Backup
- Name: Ramiro Maldonado, MD
- Phone Number: (919) 684 5631
- Email: ramiro.maldonado@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Eye Center
-
Contact:
- Michelle McCall
- Phone Number: 919-684-0544
- Email: mccal023@mc.duke.edu
-
Contact:
- Neeru Sarin
- Phone Number: 9196685641
- Email: neeru.sarin@duke.edu
-
Sub-Investigator:
- Cynthia A Toth, MD
-
Sub-Investigator:
- Mays Dairi, MD
-
Principal Investigator:
- Ramiro Maldonado, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For all participants:
- Participant's age is between 0 through 8 years (<9 years)
- Parent/legal guardian gives consents for the imaging study
- No ocular media opacities that could preclude imaging
- Refractive error equal or lower than 6 diopters
For EORD participants (Groups 1-2):
Meets clinical and molecular diagnosis of EORD (clinical determined by PI). Molecular diagnosis criteria:
- Autosomal dominant gene: One pathogenic or likely pathogenic variant that meets the clinical phenotype
- Autosomal recessive gene: two pathogenic or likely pathogenic variants in-trans which meet the phenotype.
- X-linked gene: one pathogenic or likely pathogenic variant which meets the phenotype.
For Controls (Group 3): No evidence of retinal pathology
Exclusion Criteria:
For all participants:
- Parent/legal guardian unwilling or unable to provide consent
- Refractive error higher than 6.00 diopters
- Participant has media opacities that preclude imaging
- Any non-IRD ocular condition that confound results interpretation such as glaucoma, uveitis, neurologic conditions affecting the optic nerve, etc.
For EORD participants (Groups 1-2): Does not meet molecular diagnosis criteria
For Controls (Group 3): Any suspicion of IRD
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1 - Progressive Inherited retinal dystrophy (IRD)
50 participants with progressive IRD; the most common IRD seen at Duke Clinics.
|
The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University.
OCT systems are non-contact, in-vivo optical imaging technology.
The OCT system creates real-time, non-invasive images of ocular microstructure.
OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina.
In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light.
OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds.
These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image.
These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information.
Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
Other Names:
|
Active Comparator: Group 2 - Non-progressive Inherited Retinal Dystrophy (IRD)
20 participants with non-progressive IRD (n=20), a subset of IRDs that are less frequently referred to Duke Clinics
|
The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University.
OCT systems are non-contact, in-vivo optical imaging technology.
The OCT system creates real-time, non-invasive images of ocular microstructure.
OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina.
In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light.
OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds.
These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image.
These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information.
Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
Other Names:
|
Active Comparator: Group 3 - Control participants
10 participants with normal retinal anatomy undergoing anesthesia for strabismus surgery as part of their clinically-indicated care.
|
The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University.
OCT systems are non-contact, in-vivo optical imaging technology.
The OCT system creates real-time, non-invasive images of ocular microstructure.
OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina.
In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light.
OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds.
These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image.
These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information.
Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with abnormal microanatomy as measured by OCT reading
Time Frame: Up to 24 months
|
Presence of abnormal retinal microanatomy as measured by OCT reading
|
Up to 24 months
|
Thickness of the participants retina at the fovea and surrounding optic nerve as measured by OCT reading
Time Frame: Up to 24 months
|
Retinal thickness (microns) at the fovea and surrounding optic nerve
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ramiro Maldonado, MD, Duke University Eye Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00113941
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Dystrophies
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingInherited Retinal DystrophiesChina
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingHereditary Retinal DystrophiesFrance
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingVision Functional Brain Networks in Patients With Hereditary Retinal DystrophiesFrance
-
University Hospital, MontpellierInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
Benha UniversityUnknownDystrophy, RetinalUnited Arab Emirates
-
Innostellar Biotherapeutics Co.,LtdRecruitingInherited Retinal DystrophyChina
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Novartis PharmaceuticalsActive, not recruitingBiallelic RPE65 Mutation-associated Retinal DystrophyJapan
-
Sultan Qaboos UniversityCompleted
-
PYC TherapeuticsRecruitingRetinal Dystrophy | PRPF31 Mutationassociated Retinal Dystrophy | RP11United States
Clinical Trials on SS-HH-OCT
-
Johannes Kepler University of LinzRecruitingMacular Degeneration | Diabetic Retinopathy | Retinal DiseaseAustria
-
Topcon CorporationCompletedFluorescein Angiography ImagingUnited States
-
Kubota Vision Inc.WithdrawnMacular Degeneration | Macular EdemaUnited States
-
Kubota Vision Inc.CompletedMacular Degeneration | Macular EdemaSwitzerland
-
Boston Image Reading CenterRecruitingDry Macular DegenerationUnited States, Australia
-
The University of Hong KongBiosensors InternationalRecruiting
-
Boston Image Reading CenterActive, not recruiting
-
Tomey CorporationCompletedEvaluate the Agreement and Precision of Device SS-1000 and the Predicate Device the Pentacam in a Reproducibility and Repeatability TrialJapan
-
Johns Hopkins UniversityNational Eye Institute (NEI)RecruitingRetinal Vascular Disorder | Diabetic Retinopathy | Retinal Vein Occlusion | Hypertension,EssentialUnited States
-
Moorfields Eye Hospital NHS Foundation TrustCompletedRetinal Diseases | Vitreous Diseases | Choroidal DiseasesUnited Kingdom